SCHEMBL4083770

SCHEMBL4083770

Cc1ccc2c(c1)c(C(=O)C(=O)N(Cc1ccc(Cl)cc1Cl)c1ccccc1)c(C)n2Cc1ccc(Cl)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.45
FAAH O00519 1/20 0.41
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPT P10636 4/20 0.40
ALDH1A1 P00352 2/20 0.40
ALOX12 P18054 1/20 0.40
PLA2G2A P14555 1/20 0.39
KMT2A Q03164 1/20 0.39
CCR2 P41597 1/20 0.39
PTGDR2 Q9Y5Y4 6/20 0.38
AKR1B1 P15121 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
GAA P10253 2/20 0.38
PKM P14618 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4083578 0.85 FAAH (0.55) FAAHLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL2000424 0.74 POLB (0.56) L3MBTL1FAAHMAPTALDH1A1KMT2A
SCHEMBL5445917 0.74 LMNA (0.56) L3MBTL1LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL2168096 0.73 FAAH (0.55) L3MBTL1FAAHMAPTALDH1A1KMT2A
SCHEMBL2994451 0.73 FAAH (0.48) L3MBTL1FAAHLMNASMN1; SMN2MAPT
SCHEMBL3001079 0.73 MAPT (0.47) L3MBTL1FAAHLMNAMAPTALDH1A1
SCHEMBL2004529 0.73 L3MBTL1 (0.43) L3MBTL1FAAHLMNASMN1; SMN2MAPT
SCHEMBL2005482 0.72 L3MBTL1 (0.42) L3MBTL1FAAHLMNASMN1; SMN2MAPT
SCHEMBL3000056 0.71 FAAH (0.50) L3MBTL1FAAHLMNASMN1; SMN2MAPT
SCHEMBL2168611 0.70 PLA2G2A (0.56) FAAHLMNAMAPTALDH1A1PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118503-A1 FAAH INHIBITORS FAAH, FAAH2, CNR2 L3MBTL1 2963/4885FAAH 1/4885LMNA 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.